Pneumococcal conjugate vaccines and dosing regimens in India: a perspective on evidence-based choices for pediatric immunization
DOI:
https://doi.org/10.18203/2349-3291.ijcp20261926Keywords:
Pneumococcal, PCV, Primary doses, Booster, Serotypes, Vaccine effectivenessAbstract
In India, Pneumococcal infections account for significant under 5 years health burden and mortality. Immunization with the Pneumococcal conjugate vaccine (PCV) is the best prevention method especially in developing countries where complications and hospitalization rates are high. Available vaccines include PCV10, PCV13 and PCV14 while approved dosage regimens range from 2 or 3 primary (p) doses with or without booster. The objective of this review is to compare different valency vaccines based on their serotype data and protection, as well as understand the immune protection of different primary regimens and the importance of the booster dose in the PCV immunization schedule.
References
Wahl B, Knoll MD, Shet A, Gupta M, Kumar R, Liu L, et al. National, regional and state-level pneumonia and severe pneumonia morbidity in children in India: modelled estimates for 2000 and 2015. Lancet Child Adolesc Health. 2020;4(9):678-87.
Bhat JI, Charoo BA, Mukherjee A, Ahad R, Das RR, Goyal JP, et al. Risk of hospitalization in under-five children with community-acquired pneumonia: a multicentric prospective cohort study. Indian Pediatr. 2021;58(11):1019-23.
Bokade CM, Madhura AD, Bagul AS, Thakre SB. Predictors of mortality in children due to severe and very severe pneumonia. Niger Med J. 2015;56(4):287-91.
Wahl B, Sharan A, Deloria Knoll M, Kumar R, Liu L, Chu Y, et al. National, regional and state-level burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in India: modelled estimates for 2000-2015. Lancet Glob Health. 2019;7(6):e735-47.
Manoharan A, Manchanda V, Balasubramanian S, Lalwani S, Modak M, Bai S, et al. Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study. Lancet Infect Dis. 2017;17(3):305-12.
Singh J, Sundaresan S, Manoharan A, Shet A. Serotype distribution and antimicrobial susceptibility pattern in children ≤5 years with invasive pneumococcal disease in India: a systematic review. Vaccine. 2017;35(35):4501-9.
Dhawale P, Shah S, Sharma K, Sikriwal D, Kumar V, Bhagawati A, et al. Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: do we need to revisit the pneumococcal vaccine strategy?. Hum Vaccin Immunother. 2025;21(1):2461844.
Peela SCM, Sistla S, Nagaraj G, Govindan V, Kadahalli RKL. Pre- and post-vaccine trends in pneumococcal serotypes and antimicrobial resistance patterns. Indian J Med Res. 2024;160(4):354-61.
Govindan V, Ganaie F, Nagaraj G, Hussain A, Ravi Kumar KL. Pan-India distribution of pneumococcal serotypes (PIDOPS) causing invasive pneumococcal disease and pneumonia in children between 6 weeks and 5 years and their antimicrobial resistance – Phase I. Pediatr Infect Dis. 2016;8(2):47-51.
Varghese R, Veeraraghavan B, Jeyaraman Y, Kumar G, Arora NK, Balasubramanian S. Pneumococcal conjugate vaccine rollout in India: expectations and challenges. Indian J Med Microbiol. 2019;37(2):141-6.
Nagaraj G, Govindan V, Ganaie F, Venkatesha VT, Hawkins PA, Gladstone RA, et al. Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach. Microb Genom. 2021;7(9):000645.
Apte A, Dayma G, Naziat H, Williams L, Sanghavi S, Uddin J, et al. Nasopharyngeal pneumococcal carriage in South Asian infants: results of observational cohort studies in vaccinated and unvaccinated populations. J Glob Health. 2021;11:04054.
Matur RV, Thuluva S, Gunneri S, Yerroju V, Reddy Mogulla R, Thammireddy K, et al. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8-week-old healthy Indian infants: a single-blind, randomized, active-controlled, phase III study. Vaccine. 2024;42(13):3157-65.
Thuluva S, Matur RV, Gunneri S, Ningaiah S, Yerroju V, Mogulla RR, et al. Immunogenicity and safety of Biological E’s 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p+1 schedule to healthy infants: a multicenter, randomized, active-controlled, single-blind, phase III trial. Lancet Reg Health Southeast Asia. 2026;46:100746.
Pai UA, Kasi SG, Narayanan N. A randomized, double-blind, multicenter phase III study assessing immunogenicity and safety of 3 primary doses of 13-valent pneumococcal conjugate vaccine (PCV13-TT) versus reference PCV13 in healthy infants. PEDICON. 2026.
Pai UA, Kasi SG, Patel N, Narayanan N. Pneumococcal conjugate vaccines in India: reviewing disease burden, serotypes, vaccine choice and dosing schedules. Asian J Pediatr Res. 2025;15(3):52-65.
Bennett JC, Deloria Knoll M, Kagucia EW, Garcia Quesada M, Zeger SL, Hetrich MK, et al. PSERENADE Team. Global impact of 10-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025;25(4):457-70.
Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: serotype 3 pneumococcal disease. Front Cell Infect Microbiol. 2020;10:613287.
Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135-43.
Hu R, Liu Y, Zhang L, Kang G, Xu B, Li M, et al. post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China. Front Public Health. 2023;11:1272562.
WHO. Vaccination schedule for Pneumococcal Disease. Available at: https://immunizationdata.who.int/global/wiise-detail-page/vaccination-schedule-for-pneumococcal-disease?ISO_3_CODE=&TARGETPOP_GENERAL=. Accessed on 20 April 2026.
ACVIP.org. Pneumococcal Conjugate Vaccines (PCVs): IAP Advisory Committee on Vaccines and Immunization Practices. 2021. Available at: https://acvip.org/professional/columns/pcvs-vaccines. Accessed on 20 April 2026.
Kaur R, Pichichero M. Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine. Vaccine. 2020;38(28):4423-31.
Scott P, Rutjes AW, Bermetz L, Robert N, Scott S, Lourenço T, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine. 2011;29(52):9711-21.
Zhu F, Hu Y, Li J, Ye Q, Young MM, Liang JZ, et al. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China. Pediatr Infect Dis J. 2019;38(11):1150-8.
Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33(2)S152-60.
Feemster K, Weaver J, Buchwald U, Banniettis N, Cox KS, McIntosh ED, et al. Pneumococcal Vaccine Breakthrough and Failure in Infants and Children: A Narrative Review. Vaccines (Basel). 2023;11(12):1750.
Russell FM, Chokephaibulkit K. Will two doses of pneumococcal conjugate vaccine be enough?. Lancet Infect Dis. 2024;24(5):449-51.
Wiese AD, Grijalva CG. To boost or not to boost? lessons from the Australian pneumococcal conjugate vaccination program. Clin Infect Dis. 2020;70(12):2616-8.
Blyth CC, Jayasinghe S, Andrews RM. A rationale for change: an increase in invasive pneumococcal disease in fully vaccinated children. Clin Infect Dis. 2020;70:680-3.
Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67:367-74.
Chapman TJ, Pichichero ME, Kaur R. Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine. Hum Vaccin Immunother. 2020;16(12):3201-7.
Li G, Ren T, Zhang H, Ti J, Chang X, Yin S, et al. Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine. Vaccine. 2024;42(24):126209.
Ye Q, Li H, Xie Z, Gao X, Yuan L, Chen J, et al. Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT). Vaccine. 2025;49:126815.
Kumar P, Ray A, Kumari A, Sultana A, Hora R, Singh K, et al. Chronicling the journey of pneumococcal conjugate vaccine introduction in India. Vaccines. 2025;13(4):432.
Downloads
Published
How to Cite
Issue
Section
